AVEO Pharmaceuticals, Inc.
Anti-ERBB3 antibodies
Last updated:
Abstract:
Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
Status:
Grant
Type:
Utility
Filling date:
2 Mar 2017
Issue date:
3 Dec 2019